A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
Phase of Trial: Phase III
Latest Information Update: 28 Oct 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 1 Apr 2019 to 15 Apr 2019.
- 16 Oct 2017 Planned primary completion date changed from 1 Apr 2019 to 15 Apr 2019.
- 10 Jun 2017 Biomarkers information updated